Endoscopic Ethanol Ablation of Communicating Pancreatic Cystic Neoplasms
Primary Purpose
Neoplasms, Cystic, Mucinous, and Serous, Pancreatic Neoplasms, Ultrasonography, Interventional
Status
Withdrawn
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
EUS and/or ERCP with ethanol injections of pancreatic cyst
Sponsored by
About this trial
This is an interventional treatment trial for Neoplasms, Cystic, Mucinous, and Serous focused on measuring Intraductal papillary mucinous neoplasm, Mucinous cystic neoplasm, Endoscopic ultrasound, Endoscopic retrograde cholangiopancreatography, Pancreatic cyst, Pancreas cyst, Alcohol
Eligibility Criteria
Inclusion Criteria:
- Presence of a pancreatic cystic lesion, at least 2 cm in maximum diameter
- Cyst may communicate, or definitely communicates, with the pancreatic duct (based on prior CT, MR, ERCP, or EUS images)
- Treatment of the cystic lesion is desired due to symptoms or concern for subsequent malignancy
- Age at least 18 years
- Able to give informed consent
- Surgical treatment has been considered and a surgical consultation offered to the patient, OR the subject's cyst does not meet consensus criteria for surgical resection. (Current consensus criteria for resection are one or more of the following: cyst is symptomatic, ≥ 3 cm in diameter, contains a mural nodule, cytology of cyst fluid is positive for malignancy, or main pancreatic duct diameter is > 6 mm.)
Exclusion Criteria:
- Known or suspected pregnancy, or nursing
- History of pancreatitis within 3 months prior to study endoscopy procedures
- Cyst has a primarily microcystic architecture on EUS
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Cyst ethanol lavage
Arm Description
Subjects receiving the study intervention
Outcomes
Primary Outcome Measures
Occurrence of adverse events requiring treatment or hospitalization
Decrease in volume of the pancreatic cyst by cross-sectional imaging studies (CT or MR) performed before and after treatment
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01057355
Brief Title
Endoscopic Ethanol Ablation of Communicating Pancreatic Cystic Neoplasms
Official Title
Endoscopic Ethanol Ablation of Communicating Pancreatic Cystic Neoplasms
Study Type
Interventional
2. Study Status
Record Verification Date
September 2014
Overall Recruitment Status
Withdrawn
Why Stopped
slow accural
Study Start Date
January 2010 (undefined)
Primary Completion Date
June 2013 (Actual)
Study Completion Date
June 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Mayo Clinic
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Pancreatic cysts are common, and some pancreas cysts have malignant potential. Usual treatment of these cysts is either observation or surgical removal of part or all of the pancreas. Minimally invasive treatment via endoscopy has been described, using endoscopic ultrasound (EUS) guided ethanol injections. Such studies exclude cysts that communicate with the main pancreatic duct, to avoid burning the main pancreatic duct with ethanol. In this study, pancreas cysts communicating with the main pancreas duct are treated with ethanol via endoscopic retrograde cholangiopancreatography (ERCP) and/or EUS.
Detailed Description
Subjects will undergo EUS and/or ERCP as outpatients. For cysts shown to communicate with the main pancreas duct, a balloon catheter will be placed in the main pancreatic duct via ERCP. The balloon catheter will isolate the cyst from the main pancreatic duct, allowing ethanol injections of the cyst. A pancreatic duct stent will be placed in some patients, requiring repeat endoscopy for removal at another time.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Neoplasms, Cystic, Mucinous, and Serous, Pancreatic Neoplasms, Ultrasonography, Interventional
Keywords
Intraductal papillary mucinous neoplasm, Mucinous cystic neoplasm, Endoscopic ultrasound, Endoscopic retrograde cholangiopancreatography, Pancreatic cyst, Pancreas cyst, Alcohol
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Cyst ethanol lavage
Arm Type
Experimental
Arm Description
Subjects receiving the study intervention
Intervention Type
Procedure
Intervention Name(s)
EUS and/or ERCP with ethanol injections of pancreatic cyst
Other Intervention Name(s)
Alcohol lavage, Alcohol injection, Ethanol lavage, Ethanol injection, Endoscopic treatment, Pancreas cyst ablation
Intervention Description
Lavage of cyst with 80% ethanol
Primary Outcome Measure Information:
Title
Occurrence of adverse events requiring treatment or hospitalization
Time Frame
3 days, 30 days
Title
Decrease in volume of the pancreatic cyst by cross-sectional imaging studies (CT or MR) performed before and after treatment
Time Frame
6 months, 12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Presence of a pancreatic cystic lesion, at least 2 cm in maximum diameter
Cyst may communicate, or definitely communicates, with the pancreatic duct (based on prior CT, MR, ERCP, or EUS images)
Treatment of the cystic lesion is desired due to symptoms or concern for subsequent malignancy
Age at least 18 years
Able to give informed consent
Surgical treatment has been considered and a surgical consultation offered to the patient, OR the subject's cyst does not meet consensus criteria for surgical resection. (Current consensus criteria for resection are one or more of the following: cyst is symptomatic, ≥ 3 cm in diameter, contains a mural nodule, cytology of cyst fluid is positive for malignancy, or main pancreatic duct diameter is > 6 mm.)
Exclusion Criteria:
Known or suspected pregnancy, or nursing
History of pancreatitis within 3 months prior to study endoscopy procedures
Cyst has a primarily microcystic architecture on EUS
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mark Topazian, M.D.
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Endoscopic Ethanol Ablation of Communicating Pancreatic Cystic Neoplasms
We'll reach out to this number within 24 hrs